NXT USA, the distributor and marketer of Xeya Modern Shatavari, a 15% shatavarin extract, announced the adoption of an independent testing method for this ingredient, done in conjunction with analytical testing laboratory Twin Arbor Labs.

The two companies validated the testing methodology that was developed by Laila Nutra, the India-based supplier partner of Xeya, to independently validate the methodology and performance of the testing.

“This allows our customers independent validation of our raw material, something that’s missing in the market,” said Eric Anderson, managing director of NXT USA. “You should have independent labs run methods and confirm the active content of ingredients.”

The specialized analytical method validated by Twin Arbor Labs is designed to quantify total shatavarins by specifically isolating and measuring four distinct shatavarin compounds. This level of third-party verification is increasingly important as demand grows for transparent, science-backed botanical ingredients in women’s health, the company reported.

Aligning third-party analytical validation with clinical research ensures that every batch reflects the same composition used in human trials, NXT USA reported, delivering consistent, clinically aligned support for women’s health.

Twin Arbor’s test results aligned extremely well with the baseline data provided by Laila Nutra, based on HPLC-ELSD testing. “Accurate quantification of shatavarins is critical for. Verifying the potency and quality of Asparagus racemosus botanical ingredients,” said Christopher Gray, PhD, chief operating officer and quality control director at Twin Arbor Labs. “The strong interlaboratory agreement and the successful verification using the Shatavarin IV CRM demonstrate that the method is robust and transferable.”

The analytical approach can evaluate full shatavarin composition, and is only available to Xeya customers.

Strengthening Confidence in Clinical Results

Xeya Modern Shatavari is supported by randomized, double-blind, placebo-controlled clinical trials in women with PCOS and in perimenopausal women, demonstrating improvements in vasomotor symptoms, menstrual discomfort, and quality of life.

Clinical studies confirmed measurable effects on key reproductive hormones, including FSH, LH, AMH, and estradiol, alongside improvements in ovarian follicle count and patient-reported outcomes.

By pairing the clinical studies with independent lab testing, NXT USA provides reinforcement to the whole life cycle of the ingredient, from raw material sourcing to finished extract.

Twin Arbor Labs has ensured that the analytical methods used to assess Xeya accurately address botanical identification, verified levels of active compounds, absence of contaminants and adulterants, and consistency across production batches.

“Clinical results are only as meaningful as the material behind them,” said Anderson. “Partnering with Twin Arbor Labs allows us to independently confirm that every batch of Xeya Modern Shatavari meets the same standards used in our clinical research. This is how we uphold our commitment to delivering ingredients that are not only effective, but also verifiable, reproducible, and trusted by our partners.”